Ï㽶ÊÓƵ

November 21st - Mark Miller

Seminar + Social WAAW special

Co-hosted with theÌýJD Maclean Centre of Tropical and Geographic MedicineÌý

November 21, 2024 | 4:00pm - 5:15 pm
Hybrid event - registration required

Free In-person:ÌýRI-MUHC - Cruess Auditorium (Block E, ES1.1129)
1001 Decarie Boulevard, Montreal
Online:ÌýZoom link sent to registered participants

Networking ReceptionÌý

Program:

"Antimicrobial resistance: the silent pandemic and the role of diagnostics in the battle to sustain antibiotics and save lives."Ìý
Mark Miller, MD, FRCP(C) | Independent Industry Consultant, Internist, Microbiologist, Infectious Diseases Clinician
Former Executive VP and Chief Medical Officer, bioMérieux SA, Lyon, France

Panel Discussion:

• Mark Miller,ÌýIndependent Industry Consultant
• Peter J Dailey, Berkeley School of Public Health, University of California
• David Juncker,ÌýChair Biomedical Engineering Dept., Ï㽶ÊÓƵ

About our speaker:

Dr. Miller, originally from Montreal, Canada, has had a unique 35-year medical career which has been a high-level combination of clinical, academic, and industrial experiences. He is a physician with training and certification in Internal Medicine, Infectious Diseases, and Medical Microbiology. In addition, he possesses a Master’s degree in Epidemiology & Biostatistics.

During his hospital-based 25-year academic career, he was the Chairman of 4 departments containing over 70 people in: Clinical Infectious Diseases (ID), Clinical Microbiology (Micro), ID/Micro Research, and Infection Prevention & Control. He was a full-time clinician, administrator, and researcher (novel antiinfectives and vaccines, innovative infectious disease diagnostics, and the epidemiology of healthcare-associated infections). In the latter role, he was a primary or co-author of over 150 peer-reviewed publications and over 160 presentations and was the co-discoverer of the novel hyper-virulent C. difficile strain NAP1/027 which was described in the New England Journal of Medicine in 2005. He was granted a full Professorship in the Department of Medicine at Ï㽶ÊÓƵ in 2011.

In his subsequent 12-year career (2012-2024) as Chief Medical Officer and Executive Vice President at the French head office of bioMérieux, a global in vitro diagnostics company, he created from scratch the departments of Medical Affairs, Public & Government Affairs, Patient Value Strategy, and Companion Diagnostics. For these functions, he oversaw more than 140 people and an annual budget of approximately 26 million Euros, with a focus on defining, advancing, and demonstrating the medical value and health benefits of diagnostics for improving outcomes for patients, healthcare institutions and the entire medical system.

His distinctive academic-industrial knowledge and experiences have allowed him to participate in many global, national and regional activities to improve the success of translational research to reach patients, improve global capabilities for diagnostic biopreparedness related to infectious pathogens, and to be involved in the creation of dozens of clinical diagnostics for the benefit of patients world-wide.

Currently semi-retired since January 2024, he is an independent consultant or on the Scientific Advisory Board for several companies involved with antimicrobials, vaccines, and infectious disease diagnostics.

About our panelists:

Dr. Peter J. Dailey is a microbiologist who an adjunct professor at the University of California, Berkeley School of Public Health. He is an independent consultant for CARB-X and FIND – the global alliance for diagnostics. He has 35 years of experience in infectious disease, primarily in the research and development of infectious disease molecular diagnostics. He has led the research and development of over 20 commercial diagnostic and blood-screening assays for infectious diseases at Chiron, Roche Diagnostics, and Cepheid.

David Juncker is a Canada Research Chair in Bioengineering and Professor, serving as Chair of Biomedical Engineering at Ï㽶ÊÓƵ. He earned a Diploma in Electronics-Physics from the Institute of Microtechnology at the University of Neuchatel (now part of EPFL). After a year at Japan's National Research Laboratory of Metrology, he completed his PhD at IBM Zurich under Dr. Delamarche, followed by a postdoc at ETHZ. Joining McGill as faculty, his lab focuses on pioneering micro- and nanobioengineering technologies to improve health. Juncker's team has developed innovations like microfluidic probes, thread-based microfluidics, and multiplexed, cross-reactivity-free immunoassays, leading to two spin-offs, including Nomic Bio. now explores extracellular vesicles and lipid nanoparticles, developing novel technologies for their analysis.

Ìý